Detalhe da pesquisa
1.
The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis.
Nat Immunol
; 25(4): 622-632, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38454157
2.
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
Immunity
; 53(6): 1315-1330.e9, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275896
3.
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments.
Mol Cancer
; 23(1): 53, 2024 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38468291
4.
A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.
Adv Sci (Weinh)
; 10(27): e2301034, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526323
5.
Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
Front Immunol
; 13: 992062, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36569949
6.
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.
Cell Rep
; 38(3): 110256, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34990583
7.
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.
Adv Sci (Weinh)
; 9(11): e2105378, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35142444
8.
Taohong Siwu decoction for femoral head necrosis: A protocol for systematic review.
Medicine (Baltimore)
; 99(13): e19368, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32221063
9.
Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.
Cell Mol Immunol
; 18(8): 2042-2044, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34282299
10.
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.
Cell Mol Immunol
; 18(4): 1058-1060, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33580167